Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.

@article{Gragnani2014TripleAT,
  title={Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.},
  author={L Gragnani and Alessio Fabbrizzi and E. P. D. R. Triboli and Teresa Urraro and Barbara Boldrini and Elisa Fognani and Alessia Piluso and Patrizio Caini and Jessica Ranieri and Monica Monti and Giacomo Laffi and Anna Linda Zignego},
  journal={Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
  year={2014},
  volume={46 9},
  pages={833-7}
}
BACKGROUND Mixed cryoglobulinaemia is strongly related to hepatitis C virus infection. Treatment with peg-interferon and ribavirin has been indicated as first-line therapy for mild/moderate hepatitis C virus-related mixed cryoglobulinaemia. AIM To evaluate the safety and efficacy of triple boceprevir-based antiviral therapy in patients with or without mixed cryoglobulinaemia previously treated with peg-interferon and ribavirin, and with advanced liver disease. METHODS Thirty-five hepatitis… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Systemic manifestations of hepatitis C infection

Infectious Agents and Cancer • 2016
View 15 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 30 references

HCV and Lymphoproliferation

Clinical & developmental immunology • 2012

Similar Papers

Loading similar papers…